Clofazimine does not lead to significant QT interval prolongation: a multicentre study. Issue 5 (1st November 2018)

• Record Type: Journal Article
• Authors: Zweijpfenning, Sanne M.H.; van Groningen, Hester; van Ingen, Jakko; Magis-Escurra, Cecile; Boeree, Martin J.; Wagner, Dirk; Bax, Hannelore; Andrejak, Claire; Wener, Reinier; Rahman, Ananna; Kunst, Heinke; Lorent, Natalie; Brouwer, Marc A.; Hoefsloot, Wouter
• Is Part Of: European respiratory journal. Volume 52:Issue 5(2018)
• Publication Date: 2018-11-01
• Subjects: Respiratory organs -- Diseases -- Periodicals; Respiration -- Periodicals; 616.2
• DOI: 10.1183/13993003.01386-2018
• Languages: English
• ISSNs: 0903-1936

Abstract

We read with great interest the article by Pontali et al. [1], entitled "Cardiac safety of bedaquiline: a systematic and critical analysis of the evidence". In response to this paper and the debate on potential QTc prolongation in clofazimine- and bedaquiline-containing multidrug-resistant tuberculosis (MDR-TB) treatment regimens [2, 3], we assessed QTc prolongation during clofazimine use in treatment of disease caused by nontuberculous mycobacteria (NTM). This is important as NTM disease treatment typically includes multiple potential QTc-prolonging antibiotics, including macrolides, fluoroquinolones and, increasingly, clofazimine [4]. Clofazimine does not lead to significant QT interval prolongation in the treatment of nontuberculous mycobacteria http://ow.ly/sXC330lIbI8